EML:NASDAQEastern Company (The) Analysis
Data as of 2026-06-17 - not real-time
$21.92
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The Eastern Company (EML) trades at $21.92, notably above its DCF‑derived fair value of $14.35, indicating a pricing premium of roughly 55%. Technical signals are mixed: the price sits above the 20‑day (21.48) and 50‑day (21.66) SMAs, the MACD histogram is positive (0.04) and labeled bullish, while the 30‑day volatility is elevated at 32% and the beta is modest at 0.61, suggesting limited systematic risk but high price swings. Fundamentally, revenue has declined 5.7% YoY, margins are thin (gross 22.3%, operating 2.1%), and the company carries $53.5 M of debt versus $7.6 M of cash, yielding a debt‑to‑equity of 42.9. The dividend yield of 2.01% is supported by a 56% payout ratio and positive free cash flow of $9.98 M, making the payout reasonably sustainable. Recent strategic news – the acquisition of Sungear and Crown Precision for $7.85 M to build a fourth platform focused on aerospace and defense – could improve top‑line growth and margin profile, but the integration risk and current earnings weakness temper optimism. Overall, the stock appears overvalued relative to intrinsic estimates, with modest upside potential limited by valuation gap, yet the dividend and low beta provide a defensive cushion.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above short‑term averages but limited upside to resistance at $22.38
- Bullish MACD yet high short‑term volatility
- Dividend yield provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Acquisition of aerospace/defense platforms may lift revenue growth
- Improved earnings potential could narrow valuation gap
- Sustained dividend and low beta support a moderate risk profile
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Current market price remains well above DCF fair value
- Debt load and thin margins limit upside without clear earnings acceleration
- Dividend yield and defensive beta provide stability over time
Key Metrics & Analysis
Financial Health
Revenue Growth-5.70%
Profit Margin2.38%
P/E Ratio28.1
ROE3.83%
ROA3.17%
Debt/Equity42.93
P/B Ratio1.1
Op. Cash Flow$13.8M
Free Cash Flow$10.0M
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI55.0
Support$20.37
Resistance$22.38
MA 20$21.48
MA 50$21.66
MA 200$20.73
MACDBullish
VolumeIncreasing
Fear & Greed Index88.5
Valuation
Fair Value$14.35
GradeOvervalued
TypeValue
Dividend Yield2.01%
Risk Assessment
Beta0.61
Volatility32.42%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.